Ovarian mixed germ cell neoplasm

disease
On this page

Also known as mixed germ cell neoplasm of ovarymixed germ cell neoplasm of the ovarymixed germ cell tumormixed germ cell tumor of ovarymixed germ cell tumor of the ovarymixed germ cell tumourmixed germ cell tumour of ovarymixed germ cell tumour of the ovaryovarian mixed germ cell tumorovarian mixed germ cell tumourovary mixed germ cell tumorovary mixed germ cell tumour

Summary

Ovarian mixed germ cell neoplasm (MONDO:0003710) is a cancer and 7 clinical trials. Top therapeutic interventions include ifosfamide and etoposide phosphate. A subtype of ovarian primitive germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameovarian mixed germ cell neoplasm
Mondo IDMONDO:0003710
DOIDDOID:5936
NCITC8114
UMLSC0280135
MedGen83602
GARD0023629
Anatomy (UBERON)UBERON:0000992
Is cancer (heuristic)yes

Also known as: mixed germ cell neoplasm of ovary · mixed germ cell neoplasm of the ovary · mixed germ cell tumor · mixed germ cell tumor of ovary · mixed germ cell tumor of the ovary · mixed germ cell tumour · mixed germ cell tumour of ovary · mixed germ cell tumour of the ovary · ovarian mixed germ cell neoplasm · ovarian mixed germ cell tumor · ovarian mixed germ cell tumour · ovary mixed germ cell tumor · ovary mixed germ cell tumour

Data availability: 8 cell lines · 10 intOGen driver records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancermalignant germ cell tumormalignant germ cell tumor of ovary › ovarian primitive germ cell tumor › ovarian mixed germ cell neoplasm

Related subtypes (3): dysgerminoma of ovary, non-gestational ovarian choriocarcinoma, malignant non-dysgerminomatous germ cell tumor of ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified3
PHASE12
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02375204PHASE3ACTIVE_NOT_RECRUITINGStandard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT04684368PHASE2RECRUITINGA Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT00060372PHASE1COMPLETEDIpilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT00638898PHASE1COMPLETEDBusulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
NCT05564026Not specifiedRECRUITINGMolecular Epidemiology of Pediatric Germ Cell Tumors
NCT01080521Not specifiedCOMPLETEDChanges in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01434355Not specifiedCOMPLETEDDNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
IFOSFAMIDE42
ETOPOSIDE PHOSPHATE41